| ID | JOS-bpb.b20-00986 |
| 著者：名前 | |
| 著者：別形式 | Negishi, Akio / Oshima, Shinji / Horii, Norimitsu / Mutoh, Mizue / Inoue, Naoko / Numajiri, Sachihiko / Ohshima, Shigeru / Kobayashi, Daisuke |
| 著者：カナ | |
| 著者：所属 | 城西大学薬学部薬学科薬剤作用解析学研究室 / 城西大学薬学部薬学科薬剤作用解析学研究室 / 城西大学薬学部薬学科薬局管理学研究室 / 城西大学薬学部薬学科薬局管理学研究室 / 城西大学薬学部薬学科薬局管理学研究室 / 城西大学薬学部薬学科教育支援室 / 城西大学薬学部薬学科薬局管理学研究室 / 城西大学薬学部薬学科薬剤作用解析学研究室 |
| 著者：所属(別形式） | Josai University, Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Analytical Pharmaceutics and Informatics / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Analytical Pharmaceutics and Informatics / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Pharmacy Management / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Pharmacy Management / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Pharmacy Management / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences, Student Learning Assistance Center / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Pharmacy Management / Josai University, Faculty of Pharmacy and Pharmaceutical Sciences, Laboratory of Analytical Pharmaceutics and Informatics |
| 著者版フラグ | publisher |
| 出版地 | 東京 |
| 出版者 | 日本薬学会 |
| 出版者：カナ | ニホンヤクガクカイ |
| 出版者：別名 | The Pharmaceutical Society of Japan |
| NCID | AA10885497 |
| 冊子ISSN | 09186158 |
| 電子ISSN | 13475215 |
| 掲載誌名 | |
| 巻 | 44 |
| 号 | 7 |
| 刊行年月 | 2021-07 |
| 開始ページ | 932 |
| 終了ページ | 936 |
| コンテンツ作成日 | 2020-12-05 |
| コンテンツ修正日 | 2021-04-25 |
| コンテンツ登録日 | 2021-09-21 |
| 識別番号：DOI | info:doi/10.1248/bpb.b20-00986 |
| 識別番号：DOI（リンク） | |
| PubMed番号 | 33967165 |
| NII論文ID | 130008060356 |
| 抄録 | The “INTERACTIONS” section of package inserts aims to provide alert-type warnings in clinical practice; however, these also include many drug–drug interactions that occur rarely. Moreover, considering that drug–drug interaction alert systems were created based on package inserts, repeated alerts can lead to alert fatigue. Although investigations have been conducted to determine prescriptions that induce drug–drug interactions, no studies have focused explicitly on the adverse events induced by drug–drug interactions. We, therefore, sought to investigate the true occurrence of adverse events caused by drug pair contraindications for coadministration in routine clinical practice. Toward this, we created a list of drug combinations that were designated as “contraindications for coadministration” and extracted the cases of adverse drug events from the Japanese Adverse Drug Event Report database that occurred due to combined drug usage. We then calculated the reporters’ recognition rate of the drug–drug interactions. Out of the 2121 investigated drug pairs, drug–drug interactions were reported in 43 pairs, 23 of which included an injected drug and many included catecholamines. Warfarin potassium and miconazole (19 reports), azathioprine and febuxostat (11 reports), and warfarin potassium and iguratimod (six reports) were among the 20 most-commonly reported oral medication pairs that were contraindicated for coadministration, for which recognition rates of drug–drug interactions were high. Although these results indicate that only a few drug pair contraindications for coadministration were associated with adverse drug events (43 pairs out of 2121 pairs), it remains necessary to translate these findings into clinical practice. |
| キーワード | |
| 注記 | V709210006<Pre 医中誌> |
| 言語 | eng |
| 資源タイプ | text |
| ジャンル | |
| フォーマット | application/pdf |
| 権利 | Copyright © 2021 The Pharmaceutical Society of Japan |
| このアイテムを表示する：本文(pdf) | |
| このアイテムを表示する：URI | |
